<em>In vitro</em> induction of anti‑lung cancer immune response by the A549 lung cancer stem cell lysate‑sensitized dendritic cell vaccine

Chen,Letian; Rao,Wei; Chen,Yujuan; Xie,Junping

doi:10.3892/ol.2024.14683

In vitro induction of anti‑lung cancer immune response by the A549 lung cancer stem cell lysate‑sensitized dendritic cell vaccine

Authors:
- Letian Chen
- Wei Rao
- Yujuan Chen
- Junping Xie
View Affiliations

Affiliations: Department of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330000, P.R. China, Department of Urology, Yingtan People's Hospital, Yingtan, Jiangxi 335000, P.R. China, Department of Pulmonary and Critical Care Medicine, Gaoan People's Hospital, Yichun, Jiangxi 336000, P.R. China
Published online on: September 13, 2024 https://doi.org/10.3892/ol.2024.14683
Article Number: 550
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung adenocarcinoma is one of the most fatal types of cancer worldwide, with non‑small cell lung cancer being the most common subtype. Therefore, there is need for improved treatment approaches. Tumor growth results from the proliferation of a very small number of tumor stem cells, giving rise to the theory of cancer stem cells (CSCs). Lung CSCs are associated with lung cancer development, and although chemotherapy drugs can inhibit the proliferation of lung cancer cells, they have difficulty acting on lung CSCs. Even if the tumor appears to have disappeared after chemotherapy, the presence of a small number of residual tumor stem cells can lead to cancer recurrence and metastasis. Hence, targeting and eliminating lung CSCs is of significant therapeutic importance. In this study, we cultured A549 cells in sphere‑forming conditions using B27, EGF, and bFGF, isolated peripheral blood mononuclear cells (PBMCs), and induced and characterized dendritic cells (DCs). We also isolated and expanded T lymphocytes. DC vaccines were prepared using A549 stem cell lysate or A549 cell lysate for sensitization and compared with non‑sensitized DC vaccines. The content of IFN‑γ in the supernatant of cultures with vaccines and T cells was measured by ELISA. The cytotoxic effects of the vaccines on A549 cells and stem cells were assessed using the Cytotox96 assay, and the impact of the vaccines on A549 cell migration and apoptosis was evaluated using Transwell assays and flow cytometry. DC vaccines sensitized with human lung CSC lysates induced significant in vitro cytotoxic effects on A549 lung cancer cells and CSCs by T lymphocytes, while not producing immune cytotoxic effects on human airway epithelial cells. Moreover, the immune‑killing effect induced by DC vaccines sensitized with lung CSC lysates was superior to that of DC vaccines sensitized with lung cancer cells.

View Figures

View References

1	Yin W, Wang J, Jiang L and James Kang Y: Cancer and stem cells. Exp Biol Med (Maywood). 246:1791–1801. 2021. View Article : Google Scholar : PubMed/NCBI
2	Rowbotham SP, Goruganthu MUL, Arasada RR, Wang WZ, Carbone DP and Kim CF: Lung cancer stem cells and their clinical implications. Cold Spring Harb Perspect Med. 12:a0412702022.PubMed/NCBI
3	Walcher L, Kistenmacher AK, Suo H, Kitte R, Dluczek S, Strauß A, Blaudszun AR, Yevsa T, Fricke S and Kossatz-Boehlert U: Cancer stem cells-origins and biomarkers: Perspectives for targeted personalized therapies. Front Immunol. 11:12802020. View Article : Google Scholar : PubMed/NCBI
4	Zhang D, Tang DG and Rycaj K: Cancer stem cells: Regulation programs, immunological properties and immunotherapy. Semin Cancer Biol. 52:94–106. 2018. View Article : Google Scholar : PubMed/NCBI
5	Zimmermannova O, Ferreira AG, Ascic E, Velasco Santiago M, Kurochkin I, Hansen M, Met Ö, Caiado I, Shapiro IE, Michaux J, et al: Restoring tumor immunogenicity with dendritic cell reprogramming. Sci Immunol. 8:eadd48172023. View Article : Google Scholar : PubMed/NCBI
6	Bayik D and Lathia JD: Cancer stem cell-immune cell crosstalk in tumour progression. Nat Rev Cancer. 21:526–536. 2021. View Article : Google Scholar : PubMed/NCBI
7	Doherty MR, Smigiel JM, Junk DJ and Jackson MW: Cancer stem cell plasticity drives therapeutic resistance. Cancers (Basel). 8:82016. View Article : Google Scholar : PubMed/NCBI
8	Liu Y, Wang J, Chen J, Wu S, Zeng X, Xiong Q, Guo Y, Sun J, Song F, Xu J, et al: Upregulation of miR-520c-3p via hepatitis B virus drives hepatocellular migration and invasion by the PTEN/AKT/NF-κB axis. Mol Ther Nucleic Acids. 29:47–63. 2022. View Article : Google Scholar : PubMed/NCBI
9	Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F, Tripodo C, Russo A, Gulotta G, Medema JP and Stassi G: Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell. 1:389–402. 2007. View Article : Google Scholar : PubMed/NCBI
10	Dean M: ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia. 14:3–9. 2009. View Article : Google Scholar : PubMed/NCBI
11	Huang T, Song X, Xu D, Tiek D, Goenka A, Wu B, Sastry N, Hu B and Cheng SY: Stem cell programs in cancer initiation, progression, and therapy resistance. Theranostics. 10:8721–8743. 2020. View Article : Google Scholar : PubMed/NCBI
12	Shekhani MT, Jayanthy AS, Maddodi N and Setaluri V: Cancer stem cells and tumor transdifferentiation: Implications for novel therapeutic strategies. Am J Stem Cells. 2:52–61. 2013.PubMed/NCBI
13	Garvalov BK and Acker T: Cancer stem cells: A new framework for the design of tumor therapies. J Mol Med (Berl). 89:95–107. 2011. View Article : Google Scholar : PubMed/NCBI
14	Morazán-Fernández D, Mora J and Molina-Mora JA: In silico pipeline to identify tumor-specific antigens for cancer immunotherapy using exome sequencing data. Phenomics. 3:130–137. 2022. View Article : Google Scholar : PubMed/NCBI
15	Morrison BJ, Steel JC and Morris JC: Sphere culture of murine lung cancer cell lines are enriched with cancer initiating cells. PLoS One. 7:e497522012. View Article : Google Scholar : PubMed/NCBI
16	Pardoll D: Does the immune system see tumors as foreign or self? Annu Rev Immunol. 21:807–839. 2003. View Article : Google Scholar : PubMed/NCBI
17	Hinterleitner C, Strähle J, Malenke E, Hinterleitner M, Henning M, Seehawer M, Bilich T, Heitmann J, Lutz M, Mattern S, et al: Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer. Nat Commun. 12:70052021. View Article : Google Scholar : PubMed/NCBI
18	Gilboa E: DC-based cancer vaccines. J Clin Invest. 117:1195–1203. 2007. View Article : Google Scholar : PubMed/NCBI
19	Jego G, Pascual V, Palucka AK and Banchereau J: Dendritic cells control B cell growth and differentiation. Curr Dir Autoimmun. 8:124–139. 2005. View Article : Google Scholar : PubMed/NCBI
20	Qi H, Egen JG, Huang AYC and Germain RN: Extrafollicular activation of lymph node B cells by antigen-bearing dendritic cells. Science. 312:1672–1676. 2006. View Article : Google Scholar : PubMed/NCBI
21	Rojas-Sepúlveda D, Tittarelli A, Gleisner MA, Ávalos I, Pereda C, Gallegos I, González FE, López MN, Butte JM, Roa JC, et al: Tumor lysate-based vaccines: On the road to immunotherapy for gallbladder cancer. Cancer Immunol Immunother. 67:1897–1910. 2018. View Article : Google Scholar : PubMed/NCBI
22	Ragde H, Cavanagh WA and Tjoa BA: Dendritic cell based vaccines: Progress in immunotherapy studies for prostate cancer. J Urol. 172:2532–2538. 2004. View Article : Google Scholar : PubMed/NCBI
23	Ni L: Advances in human dendritic cell-based immunotherapy against gastrointestinal cancer. Front Immunol. 13:8871892022. View Article : Google Scholar : PubMed/NCBI
24	Dwivedi R, Pandey R, Chandra S and Mehrotra D: Dendritic cell-based immunotherapy: a potential player in oral cancer therapeutics. Immunotherapy. 15:457–469. 2023. View Article : Google Scholar : PubMed/NCBI
25	Yang J, Shangguan J, Eresen A, Li Y, Wang J and Zhang Z: Dendritic cells in pancreatic cancer immunotherapy: Vaccines and combination immunotherapies. Pathol Res Pract. 215:1526912019. View Article : Google Scholar : PubMed/NCBI
26	Qian D, Li J, Huang M, Cui Q, Liu X and Sun K: Dendritic cell vaccines in breast cancer: Immune modulation and immunotherapy. Biomed Pharmacother. 162:1146852023. View Article : Google Scholar : PubMed/NCBI
27	Gu JH and Li G: Dendritic cell-based immunotherapy for malignant glioma. Neurosci Bull. 24:39–44. 2008. View Article : Google Scholar : PubMed/NCBI
28	Zhang X, He T, Li Y, Chen L, Liu H, Wu Y and Guo H: Dendritic cell vaccines in ovarian cancer. Front Immunol. 11:6137732021. View Article : Google Scholar : PubMed/NCBI
29	Perrigue PM, Rakoczy M, Pawlicka KP, Belter A, Giel-Pietraszuk M, Naskręt-Barciszewska M, Barciszewski J and Figlerowicz M: Cancer stem cell-inducing media activates senescence reprogramming in fibroblasts. Cancers (Basel). 12:17452020. View Article : Google Scholar : PubMed/NCBI
30	Chometon TQ, Siqueira MDS, Sant Anna JC, Almeida MR, Gandini M, Martins de Almeida Nogueira AC and Antas PRZ: A protocol for rapid monocyte isolation and generation of singular human monocyte-derived dendritic cells. PLoS One. 15:e02311322020. View Article : Google Scholar : PubMed/NCBI
31	Kokkinopoulos D, Perez S, Sotiriadou R, Stinios J and Papamichail M: The use of nylon wool for the isolation of T lymphocyte subpopulations. J Immunol Methods. 154:1–6. 1992. View Article : Google Scholar : PubMed/NCBI
32	Luo Y, Chen J, Liu M, Chen S, Su X, Su J, Zhao C, Han Z, Shi M, Ma X and Huang H: Twist1 promotes dendritic cell-mediated antitumor immunity. Exp Cell Res. 392:1120032020. View Article : Google Scholar : PubMed/NCBI
33	Han F, Guo S, Huang C, Cui L, Zhao Y, Ma J, Zhu M, Chen Z, Wang M, Shen B and Zhu W: Gastric cancer mesenchymal stem cells inhibit natural killer cell function by up-regulating FBP1. Cent Eur J Immunol. 46:427–437. 2021. View Article : Google Scholar : PubMed/NCBI
34	In H, Park JS, Shin HS, Ryu SH, Sohn M, Choi W, Park S, Hwang S, Park J, Che L, et al: Identification of dendritic cell precursor from the CD11c⁺ cells expressing high levels of MHC class II molecules in the culture of bone marrow with FLT3 ligand. Front Immunol. 14:11799812023. View Article : Google Scholar : PubMed/NCBI
35	Wei W, Mu S, Han Y, Chen Y, Kuang Z, Wu X, Luo Y, Tong C, Zhang Y, Yang Y and Song Z: Gpr174 knockout alleviates DSS-induced colitis via regulating the immune function of dendritic cells. Front Immunol. 13:8412542022. View Article : Google Scholar : PubMed/NCBI
36	Wang Y, Xiang Y, Xin VW, Wang XW, Peng XC, Liu XQ, Wang D, Li N, Cheng JT, Lyv YN, et al: Dendritic cell biology and its role in tumor immunotherapy. J Hematol Oncol. 13:1072020. View Article : Google Scholar : PubMed/NCBI
37	Hanna JM and Onaitis MW: Cell of origin of lung cancer. J Carcinog. 12:62013. View Article : Google Scholar : PubMed/NCBI
38	Saxena M, Balan S, Roudko V and Bhardwaj N: Towards superior dendritic-cell vaccines for cancer therapy. Nat Biomed Eng. 2:341–346. 2018. View Article : Google Scholar : PubMed/NCBI
39	Bol KF, Schreibelt G, Gerritsen WR, de Vries IJ and Figdor CG: Dendritic cell-based immunotherapy: State of the art and beyond. Clin Cancer Res. 22:1897–1906. 2016. View Article : Google Scholar : PubMed/NCBI
40	Kaczmarek M, Poznańska J, Fechner F, Michalska N, Paszkowska S, Napierała A and Mackiewicz A: Cancer vaccine therapeutics: limitations and effectiveness-a literature review. Cells. 12:21592023. View Article : Google Scholar : PubMed/NCBI
41	Fu C, Zhou L, Mi QS and Jiang A: DC-based vaccines for cancer immunotherapy. Vaccines (Basel). 8:7062020. View Article : Google Scholar : PubMed/NCBI
42	Hato L, Vizcay A, Eguren I, Pérez-Gracia JL, Rodríguez J, Gállego Pérez-Larraya J, Sarobe P, Inogés S, Díaz de Cerio AL and Santisteban M: Dendritic cells in cancer immunology and immunotherapy. Cancers (Basel). 16:9812024. View Article : Google Scholar : PubMed/NCBI
43	Perez CR and De Palma M: Engineering dendritic cell vaccines to improve cancer immunotherapy. Nat Commun. 10:54082019. View Article : Google Scholar : PubMed/NCBI
44	Mastelic-Gavillet B, Balint K, Boudousquie C, Gannon PO and Kandalaft LE: Personalized dendritic cell vaccines-recent breakthroughs and encouraging clinical results. Front Immunol. 10:7662019. View Article : Google Scholar : PubMed/NCBI
45	Abraham RS and Mitchell DA: Gene-modified dendritic cell vaccines for cancer. Cytotherapy. 18:1446–1455. 2016. View Article : Google Scholar : PubMed/NCBI
46	Masoumi J, Ghorbaninezhad F, Saeedi H, Safaei S, Khaze Shahgoli V, Ghaffari Jolfayi A, Naseri B, Baghbanzadeh A, Baghbani E, Mokhtarzadeh A, et al: siRNA-mediated B7H7 knockdown in gastric cancer lysate-loaded dendritic cells amplifies expansion and cytokine secretion of autologous T cells. Biomedicines. 11:32122023. View Article : Google Scholar : PubMed/NCBI
47	Chen L, Zhang D, Chen Y, Zhu H, Liu Z, Yu Z and Xie J: ORC6 acts as an effective prognostic predictor for non-small cell lung cancer and is closely associated with tumor progression. Oncol Lett. 27:962024. View Article : Google Scholar : PubMed/NCBI
48	Campillo-Davo D, Versteven M, Roex G, De Reu H, Heijden SV, Anguille S, Berneman ZN, Tendeloo VFIV and Lion E: Rapid assessment of functional avidity of tumor-specific T cell receptors using an antigen-presenting tumor cell line electroporated with full-length tumor antigen mRNA. Cancers (Basel). 12:2562020. View Article : Google Scholar : PubMed/NCBI
49	Constantino J, Gomes C, Falcão A, Neves BM and Cruz MT: Dendritic cell-based immunotherapy: A basic review and recent advances. Immunol Res. 65:798–810. 2017. View Article : Google Scholar : PubMed/NCBI
50	Elster JD, Krishnadas DK and Lucas KG: Dendritic cell vaccines: A review of recent developments and their potential pediatric application. Hum Vaccin Immunother. 12:2232–2239. 2016. View Article : Google Scholar : PubMed/NCBI
51	Antonios JP, Soto H, Everson RG, Orpilla J, Moughon D, Shin N, Sedighim S, Yong WH, Li G, Cloughesy TF, et al: PD-1 blockade enhances the vaccination-induced immune response in glioma. JCI Insight. 1:e870592016. View Article : Google Scholar : PubMed/NCBI
52	Ge Y, Xi H, Ju S and Zhang X: Blockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice. Cancer Lett. 336:253–259. 2013. View Article : Google Scholar : PubMed/NCBI
53	Zitvogel L, Apetoh L, Ghiringhelli F, André F, Tesniere A and Kroemer G: The anticancer immune response: Indispensable for therapeutic success? J Clin Invest. 118:1991–2001. 2008. View Article : Google Scholar : PubMed/NCBI
54	Wheeler CJ, Das A, Liu G, Yu JS and Black KL: Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res. 10:5316–5326. 2004. View Article : Google Scholar : PubMed/NCBI
55	Wang S, Song Y, Shi Q, Qiao G, Zhao Y, Zhou L, Zhao J, Jiang N and Huang H: Safety of dendritic cell and cytokine-induced killer (DC-CIK) cell-based immunotherapy in patients with solid tumor: A retrospective study in China. Am J Cancer Res. 13:4767–4782. 2023.PubMed/NCBI
56	Wang S, Wang X, Zhou X, Lyerly HK, Morse MA and Ren J: DC-CIK as a widely applicable cancer immunotherapy. Expert Opin Biol Ther. 20:601–607. 2020. View Article : Google Scholar : PubMed/NCBI
57	Bhattacharyya T, Purushothaman K, Puthiyottil SS, Bhattacharjee A and Muttah G: Immunological interactions in radiotherapy-opening a new window of opportunity. Ann Transl Med. 4:512016.PubMed/NCBI
58	Ge C, Yang X, Xin J, Gong X, Wang X and Kong L: Recent advances in antitumor dendritic cell vaccines. Cancer Biother Radiopharm. 38:450–457. 2023.PubMed/NCBI